Through Navican, patients at Intermountain can get tested on an internally developed NGS platform that gauges a range of actionable genes implicated in cancer.
The test enables donor screening laboratories to use PCR-based diagnostic technology to screen donated blood and plasma.
The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.
The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.
Under the partnership, Myriad will be ION's preferred partner for providing hereditary testing to its member practices.
In Science this week: convergent evolution in bird hemoglobin, and more.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.